Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease - Chen, Ming-Han; Lee, I-Cheng; Chen, Ming-Huang; Hou, Ming-Chih; Tsai, Chang-Youh; Huang, Yi-Hsiang (Annals of the rheumatic diseases, 2021)
Keywords: abatacept; Abatacept - adverse effects; Adult; Aged; Antigens; Antirheumatic Agents - adverse effects; Arthritis, Rheumatoid - drug therapy; Biological products; Chemotherapy; Core protein; Disease prevention; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B surface antigen; Hepatitis B Surface Antigens - immunology; Hepatitis B, Chronic - immunology; Hospitals; Humans; Immunotherapy; Male; Middle Aged; Monoclonal antibodies; Multivariate analysis; Normal distribution; Patients; Reinfection - chemically induced; Reinfection - epidemiology; Reinfection - immunology; Rheumatoid arthritis; Risk factors; Rituximab; Rituximab - adverse effects; Seroconversion; Targeted cancer therapy; Tumor necrosis factor-TNF; tumour necrosis factor inhibitors; Taiwan; tumour necrosis factor inhibitors; abatacept; rituximab